Propofol Preferably Suppress Ventricular Arrhythmia Originating from Right Ventricular Outflow Tract: from Bench to Bedside
Kaibin Lin,Kankai Chen,Xue Zhang,Xiaolin Qian,Ming-qi Cai,Min-Jie Yuan,Yin Yu,Jun-chi Hu,Zu-feng Guo,Shuai Li,Yan-peng Wang,Bu-bing Zeng,Meng Wei,Yong-jun Dang,Chen Zhang,Lei Yang,Qing Wang,Huang-tian Yang,Cheng-xing Shen,Jingbo Li,Tao Xu,Dong Huang
DOI: https://doi.org/10.2139/ssrn.4267516
2022-01-01
SSRN Electronic Journal
Abstract:Background: The right ventricular outflow tract (RVOT) is the most common origin for idiopathic ventricular arrhythmias (IVAs). Propofol has shown some antiarrhythmic potentials in previous studies, but its effects on IVAs and the underlying mechanisms remain elusive. Methods and findings: Adult cardiomyocytes were obtained from different regions of the rabbit heart. RVOT suggested the shortest action potential duration (APD) and showed the lowest L-type calcium current (ICa-L) and sodium current (INa) during the early phase of action potential among the examined regions, which may contribute to its susceptibility to IVAs. After exposure to Bay-K-8644, the APD of RVOT was significantly prolonged with increased early afterdepolarizations (EADs), as compared to cardiomyocytes from other regions, while propofol abolished these differential effects on EADs via shorting the APD and the effect was more significant in RVOT. Moreover, RVOT showed the significant suppression effect of ICa-L and INa during the early phase of action potential in the presence of propofol, which account for the region-specific antiarrhythmic effects of propofol. In the clinical study, IVAs originating from RVOT tended to be suppressed by propofol than those originating from non-RVOT foci, while these effects were not observed with etomidate. Moreover, propofol was also shown to bind directly to Cav1.2, as evidenced by molecular-docking analyses. Interpretation: Propofol preferably suppress IVAs originating from the RVOT by targeting the ICa-L and INa.Trial Registration Details: The studies with clinical trials were registered in Chinese Clinical Trial Registry (ChiCTR-OOC-17011821 and ChiCTR-2000033803).Funding Information: This work was supported by grants from the National Nature Science Foundation of China (Grant/Award Numbers:81871102, 82172068, 82170314, 81974028), the Municipal Science and Technology Commission Medical Innovation Project (Grant/Award Numbers:20Y11910200) , the Research physician Program of 3- year Action Plan for Promoting Clinical Skills and Clinical Innovation in Municipal Hospitals of Shanghai Shen Kang Hospital Development Center (Grant/Award Numbers: SHDC2022CRD039), the Interdisciplinary Program of Shanghai Jiao Tong University (Grant/Award Numbers:YG2019ZDA10), Natural Science Foundation of Shanghai (Grant/Award Numbers:21ZR1448100).Declaration of Interests: The other authors have declared that no conflict of interest exists.Ethics Approval Statement: The studies were approved by the institutional review board of the ethics committee of Shanghai Jiaotong University affiliated Sixth People’s Hospital (2017-128 and 2020-099). All participants provided written informed consent. The procedures regarding animal maintenance and experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Shanghai Jiaotong University affiliated with Shanghai Sixth People's Hospital.